FederalCircuit Reverses District Court's Invalidity Ruling on Written Description in Novartis v. Torrent February 18, 2025 In a precedential opinion issued on January 10, 2025, the United States Court ...
NHK-Fintiv Rule Challenges Look Futile at FederalCircuit April 6, 2021 The NHK-Fintiv rule allows the Patent Trial and Appeal Board (PTAB) to deny institution of an inter partes review petition based ...
FederalCircuit Refuses to Construe "Configured For" as More Than "Capable Of" March 12, 2026 In In re Blue Buffalo Enterprises, Inc., No. 2024-1611 (Fed. Cir. Jan. 14, 2026), the FederalCircuit affirmed ...
here) we reported on the non-precedential FederalCircuit decision in Daiichi Sankyo Co. v. Seagen Inc., Fed. Cir. Dec 02, 2025, appeal 2023-2424, holding that Seagen’s U.S. Patent 10,808,039 (‘039)...
Supreme Court Affirms FederalCircuit Decision in Amgen v. Sanofi May 18, 2023 In a unanimous opinion the Court decided that the FederalCircuit’s decision was correct. The Court noted that that ...
FederalCircuit Remands to PTAB to Further Consider Pfizer's Motion to Amend Claims March 13, 2024 In a recent ruling regarding Pfizer's pneumococcal vaccine patent (U.S. Patent No. 9,492,559), the ...
The FederalCircuit Takes Design Patent Obviousness En Banc July 11, 2023 The FederalCircuit on June 30 granted a petition for re-hearing en banc of its per curiam decision in LKQ Corp. v. GM Global ...
The FederalCircuit Rejects PacBio's Argument that Oxford Used the Then-Emerging Global COVID-19 Crisis to Win on Invalidity for Lack of Enablement July 15, 2021 In the recent decision PacificBiosciences ...
FederalCircuit Upholds PTAB Finding of Patentability in Medtronic v. Teleflex Life Sciences April 1, 2024 In Medtronic, Inc. v. Teleflex Life Sciences Ltd. the FederalCircuit upheld the Patent Trial ...
FederalCircuit Upholds Invalidity Based on Mandatory Publication of Clinical Trial Protocol May 16, 2024 Clinical trials are a critical part of the development and approval process for drugs, biologics,...